drugset / Trial / NCT06411184
Safety and Efficacy of Treg Cell in the Treatment of GVHD
NaSingle-groupOpen-labelTreatment
Summary
This is a randomized, single-center phase 1/2a clinical trial without blinding. Regulatory T cells (Tregs) have shown potential in treating various immune-related diseases, including autoimmune disorders, transplant rejection, and inflammatory diseases. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of autologous Tregs in the treatment of GVHD.
Timeline
- Start
- 2024-06-01
- Primary completion
- 2025-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regulator T Cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | Regulator T Cells | Cell therapy | 2e+06 cells/kg | — |
| Subject | Regulator T Cells | Cell therapy | 4e+06 cells/kg | — |
| Subject | Regulator T Cells | Cell therapy | 8e+06 cells/kg | — |